ESC 2021: Late-breaking Science Video Collection
Published: 02 September 2021
SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
- ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI
- SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
- TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI
- The LAAOS III Study: Surgical AFIB Ablation Evaluation
- TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
- STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS
- SPLENDOR: Metabolic Surgery and Risk of MACE in NASH
- RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients
- VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes
- Micra CED: 2-Year Outcomes with Leadless Pacing
- RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
View from the Thoraxcenter
Late-breaker Discussion Series
Masterclass with Dr Harriette Van Spall & Dr Birgit Vogel
Adrian P Banning
Dr Adrian Banning is a consultant cardiologist specialising in percutaneous coronary intervention.
He is the president of the British Cardiac Intervention Society and was previously the Divisional Director for Cardiology, Cardiothoracic and Vascular Surgery at the John Radcliffe University Hospital, Oxford. Through his position at the John Radcliffe, and his own practice at Oxford’s The Manor Hospital, Prof Banning provides specialist regional services for coronary and valvular heart disease patients to an area of 1.2 million people.
Prof Banning is pioneering research in his field and lectures nationally and internationally. He has authored several books on coronary intervention and has more than 300 PubMed listed scientific papers to his name.